Soligenix's Heat-Stable Vaccine Platform Demonstrates Extended Stability for Filovirus Protection
TL;DR
Soligenix's ThermoVax platform offers a competitive edge with heat-stable vaccines that can be stockpiled for rapid deployment during outbreaks, reducing logistical costs.
Soligenix's ThermoVax platform maintains vaccine structural integrity and immunogenicity for at least 24 months at 40°C using proprietary protein subunit technology and stabilization methods.
Soligenix's heat-stable vaccine technology improves global health equity by enabling reliable vaccine storage in remote areas without refrigeration, saving lives during outbreaks.
Soligenix developed vaccines that remain stable for years at scorching temperatures above 40°C, potentially transforming how we respond to deadly viruses like Ebola.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. has published peer-reviewed data showing its protein subunit vaccine platform for Ebola and Marburg-related viruses maintains stability for extended periods at elevated temperatures, representing a significant advancement in biodefense preparedness. The company's ThermoVax platform demonstrated that vaccine antigens maintained structural integrity and immunogenicity after 24 months of storage at 40°C, doubling the previously demonstrated stability window of 12 months. The publication, titled 'Development of Thermostable Filovirus Vaccines Using Protein Subunit Technology,' details how Soligenix's formulations outperformed unstabilized comparators that degraded significantly under identical high-temperature conditions.
This capability to remain stable when stored for extended periods at temperatures above 40°C could fundamentally change how vaccines are distributed and stockpiled for outbreak response, particularly in regions with limited cold chain infrastructure. The development addresses critical logistical challenges in global health emergency response, where maintaining vaccine potency during transportation and storage in tropical climates has historically been a major obstacle. This research expands earlier work supported by ongoing U.S. government contracts with the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases.
The implications of this technological advancement extend beyond immediate outbreak response to long-term strategic stockpiling of medical countermeasures. By eliminating the need for continuous refrigeration, these heat-stable vaccines could be prepositioned in remote locations and remain effective for years, dramatically improving global readiness for emerging infectious disease threats. This development comes at a critical time when climate change and global travel patterns increase the risk of rapid disease transmission across international borders.
Soligenix's Public Health Solutions business segment includes development programs for multiple vaccine candidates, including RiVax for ricin toxin and CiVax for COVID-19 prevention, all incorporating the ThermoVax heat stabilization technology. The company's website at https://www.Soligenix.com provides additional information about their vaccine development programs. The extended stability data for filovirus vaccines represents a milestone in creating more resilient medical countermeasures against potential biological threats.
Curated from InvestorBrandNetwork (IBN)
